众生药业子公司一类创新药RAY1225注射液新增适应症临床试验获批准

Core Viewpoint - The announcement highlights that Zhongsheng Pharmaceutical's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for a Phase III clinical trial of its innovative polypeptide drug RAY1225 injection, targeting obesity combined with obstructive sleep apnea [1] Group 1 - RAY1225 injection is an innovative polypeptide drug developed by Zhongsheng Ruichuang, possessing global intellectual property rights [1] - The drug exhibits dual agonistic activity on GLP-1 and GIP receptors, indicating its potential effectiveness in treating obesity-related conditions [1] - RAY1225 injection is characterized by excellent pharmacokinetic properties, allowing for administration once every two weeks, showcasing its long-acting potential [1]